Literature DB >> 22394225

Lung mast cell density defines a subpopulation of patients with idiopathic pulmonary fibrosis.

Seung-Ick Cha1, Christine S Chang, Eun Kyung Kim, Jae W Lee, Michael A Matthay, Jeffrey A Golden, Brett M Elicker, Kirk Jones, Harold R Collard, Paul J Wolters.   

Abstract

AIMS: The relationship of mast cells to the pathogenesis of lung fibrosis remains undefined despite recognition of their presence in the lungs of patients with pulmonary fibrosis. This study was performed to characterize the relationship of mast cells to fibrotic lung diseases. METHODS AND
RESULTS: Lung tissues from patients with idiopathic pulmonary fibrosis (IPF), chronic hypersensitivity pneumonitis (HP), systemic sclerosis (SSc)-related interstitial lung disease (ILD) and normal individuals were subjected to chymase immunostaining and the mast cell density quantified. Eosinophils were quantified by immunostaining for eosinophil peroxidase. Changes in lung function were correlated with mast cell density. Lung tissue obtained from IPF patients had a higher density of chymase-immunoreactive mast cells than that from patients with HP, SSc-related ILD or normal lungs. IPF lung tissue had a higher density of eosinophils than normal lung. There was no correlation between mast cell density and eosinophil density in IPF lung. IPF patients with high mast cell density had a slower rate of decline in forced vital capacity (FVC) than IPF patients with low mast cell density.
CONCLUSIONS: Mast cell density in IPF lungs is higher than in other fibrotic lung diseases and normal lungs. Increased mast cell density in IPF may predict slower disease progression.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22394225      PMCID: PMC3371307          DOI: 10.1111/j.1365-2559.2012.04197.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  45 in total

Review 1.  American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 2.  American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2002-01-15       Impact factor: 21.405

3.  The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis.

Authors:  Andrew G Nicholson; Laura G Fulford; Thomas V Colby; Roland M du Bois; David M Hansell; Athol U Wells
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

4.  Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.

Authors:  Harold R Collard; Talmadge E King; Becki Bucher Bartelson; Jason S Vourlekis; Marvin I Schwarz; Kevin K Brown
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

5.  Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology.

Authors:  C Vancheri; M Failla; N Crimi; G Raghu
Journal:  Eur Respir J       Date:  2010-03       Impact factor: 16.671

6.  Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality.

Authors:  T E King; M I Schwarz; K Brown; J A Tooze; T V Colby; J A Waldron; A Flint; W Thurlbeck; R M Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

7.  Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease.

Authors:  Kevin R Flaherty; Thomas V Colby; William D Travis; Galen B Toews; Jeanette Mumford; Susan Murray; Victor J Thannickal; Ella A Kazerooni; Barry H Gross; Joseph P Lynch; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2003-02-20       Impact factor: 21.405

8.  Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.

Authors:  Yoshikazu Inoue; Talmadge E King; Elizabeth Barker; Elaine Daniloff; Lee S Newman
Journal:  Am J Respir Crit Care Med       Date:  2002-09-01       Impact factor: 21.405

9.  Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia.

Authors:  Kevin R Flaherty; Jeanette A Mumford; Susan Murray; Ella A Kazerooni; Barry H Gross; Thomas V Colby; William D Travis; Andrew Flint; Galen B Toews; Joseph P Lynch; Fernando J Martinez
Journal:  Am J Respir Crit Care Med       Date:  2003-05-28       Impact factor: 21.405

10.  Chymase inhibition prevents cardiac fibrosis and improves diastolic dysfunction in the progression of heart failure.

Authors:  Takehiro Matsumoto; Atsuyuki Wada; Takayoshi Tsutamoto; Masato Ohnishi; Takahiro Isono; Masahiko Kinoshita
Journal:  Circulation       Date:  2003-05-12       Impact factor: 29.690

View more
  25 in total

1.  A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis.

Authors:  Yasmina Bauer; John Tedrow; Simon de Bernard; Magdalena Birker-Robaczewska; Kevin F Gibson; Brenda Juan Guardela; Patrick Hess; Axel Klenk; Kathleen O Lindell; Sylvie Poirey; Bérengère Renault; Markus Rey; Edgar Weber; Oliver Nayler; Naftali Kaminski
Journal:  Am J Respir Cell Mol Biol       Date:  2015-02       Impact factor: 6.914

Review 2.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

3.  Diagnostic and therapeutic strategies for eosinophilic esophagitis.

Authors:  Asifa K Zaidi; Ahad Mussarat; Anil Mishra
Journal:  Clin Pract (Lond)       Date:  2014

Review 4.  Pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Paul J Wolters; Harold R Collard; Kirk D Jones
Journal:  Annu Rev Pathol       Date:  2013-09-13       Impact factor: 23.472

5.  Mechanical Stretch: An Important and Understudied Feature of Acute and Chronic Lung Injury.

Authors:  Leigh M Cagino; Matthew K Hensley; Sean M Fortier; Robert P Dickson
Journal:  Am J Respir Crit Care Med       Date:  2020-04-15       Impact factor: 21.405

Review 6.  Mast cell chymase: morphofunctional characteristics.

Authors:  Dmitri Atiakshin; Igor Buchwalow; Markus Tiemann
Journal:  Histochem Cell Biol       Date:  2019-08-08       Impact factor: 4.304

7.  Are mast cells implicated in asphyxia?

Authors:  Barbara Muciaccia; Cristina Sestili; Stefania De Grossi; Annarita Vestri; Luigi Cipolloni; Rossana Cecchi
Journal:  Int J Legal Med       Date:  2015-06-11       Impact factor: 2.686

8.  Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease.

Authors:  Andrew Rasky; David M Habiel; Susan Morris; Matthew Schaller; Bethany B Moore; Sem Phan; Steven L Kunkel; Martin Phillips; Cory Hogaboam; Nicholas W Lukacs
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-11-20       Impact factor: 5.464

Review 9.  Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling.

Authors:  Louis J Dell'Italia; James F Collawn; Carlos M Ferrario
Journal:  Circ Res       Date:  2018-01-19       Impact factor: 17.367

Review 10.  Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Authors:  Paul J Wolters; Timothy S Blackwell; Oliver Eickelberg; James E Loyd; Naftali Kaminski; Gisli Jenkins; Toby M Maher; Maria Molina-Molina; Paul W Noble; Ganesh Raghu; Luca Richeldi; Marvin I Schwarz; Moises Selman; Wim A Wuyts; David A Schwartz
Journal:  Lancet Respir Med       Date:  2018-02       Impact factor: 30.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.